New York – February 26, 2008 – LAWFUEL – Debevoise & Plimpton LLP is advising Galderma Pharma S.A. and its U.S. holding company, Galderma Laboratories, Inc., in connection with Galderma’s definitive agreement to purchase all of the outstanding shares of CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI), at a price of $16.60 per share in cash, in a transaction valued at approximately $420 million. The acquisition will be made pursuant to a tender offer followed by a subsequent merger. Certain holders of CollaGenex preferred stock have entered into a stock purchase and voting agreement with Galderma in connection with the transaction.
Galderma, created as a joint venture in 1981 between L’Oreal and Nestle, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. Debevoise & Plimpton LLP is a leading international law firm with offices in New York, Washington D.C., London, Paris, Frankfurt, Moscow, Hong Kong and Shanghai.
The Debevoise team is led by partner Paul S. Bird and includes partners Peter A. Furci and Jonathan F. Lewis and associates Jeremy Rossman and Jennifer Whetsell.
